BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 2426823)

  • 1. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
    Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
    Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
    Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases.
    Grossi A; Vannucchi AM; Rafanelli D; Filimberti E; Rossi Ferrini P
    Thromb Res; 1986 Aug; 43(3):367-74. PubMed ID: 2426823
    [No Abstract]   [Full Text] [Related]  

  • 7. The spectrum of myeloproliferative disorders.
    Gilbert HS
    Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
    [No Abstract]   [Full Text] [Related]  

  • 8. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 9. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 11. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum vitamin B12 binders and human marrow cell uptake of 57Co-vitamin B12.
    Nutr Rev; 1973 Sep; 31(9):277-9. PubMed ID: 4128415
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.